 Heres a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech Stocks Hitting 52-week highs on Jan. 27 10X Genomics Inc NASDAQ: TXG Achillion Pharmaceuticals, Inc. NASDAQ: ACHN announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. NASDAQ: ALXN Cidara Therapeutics Inc NASDAQ: CDTX Cleveland BioLabs, Inc. NASDAQ: CBLI saw a coronavirus-induced rally Denali Therapeutics Inc NASDAQ: DNLI Dr.Reddys Laboratories Ltd NYSE: RDY reacted to its Q3 results Inovio Pharmaceuticals Inc NASDAQ: INO announced Nevro Corp NYSE: NVRO Oyster Point Pharma Inc NASDAQ: OYST Quest Diagnostics Inc NYSE: DGX Rapt Therapeutics Inc NASDAQ: RAPT SI-Bone Inc NASDAQ: SIBN Vaccinex Inc NASDAQ: VCNX Vir Biotechnology Inc NASDAQ: VIR Down In The Dumps Biotech Stocks Hitting 52-week lows on Jan. 27 Alkermes Plc NASDAQ: ALKS Allogene Therapeutics Inc NASDAQ: ALLO Autolus Therapeutics Ltd ADR NASDAQ: AUTL Axovant Gene Therapies Ltd NASDAQ: AXGT Avanos Medical Inc NYSE: AVNS Blueprint Medicines Corp NASDAQ: BPMC Correvio Pharma Corp NASDAQ: CORV Enanta Pharmaceuticals Inc NASDAQ: ENTA Heat Biologics Inc NASDAQ: HTBX HTG Molecular Diagnostics Inc NASDAQ: HTGM Kura Oncology Inc NASDAQ: KURA Madrigal Pharmaceuticals Inc NASDAQ: MDGL MediciNova, Inc. 